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Select residues in the biantennary sugar moiety attached to the fragment crystallizable
of immunoglobulin G (IgG) antibodies can modulate IgG effector functions. Thus,
afucosylated IgG glycovariants have enhanced cytotoxic activity, whereas IgG
glycovariants rich in terminal sialic acid residues can trigger anti-inflammatory effects.
More recent evidence suggests that terminal α2,6 linked sialic acids can be attached to
antibodies post IgG secretion. These findings raise concerns for the use of therapeutic
antibodies as they may change their glycosylation status in the patient and hence
affect their activity. To investigate to what extent B cell extrinsic sialylation processes
modify therapeutic IgG preparations in vivo, we analyzed changes in human intravenous
IgG (IVIg) sialylation upon injection in mice deficient in B cells or in mice lacking the
sialyltransferase 1, which catalyzes the addition of α2,6 linked sialic acid residues. By
performing a time course of IgG glycan analysis with HILIC-UPLC-FLR (plus MS) and
xCGE-LIF our study suggests that therapeutic IgG glycosylation is stable upon injection
in vivo. Only a very small fraction of IgG molecules acquired sialic acid structures
predominantly in the Fab- but not the Fc-portion upon injection in vivo, suggesting that
therapeutic antibody glycosylation will remain stable upon injection in vivo.
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INTRODUCTION
Immunoglobulin G (IgG) antibodies are glycoproteins with pro- and anti-inflammatory effector
functions. Thus, binding of IgG to Fcγ receptors (FcγRs) can trigger effector functions such as
the release of pro-inflammatory mediators, phagocytosis of opsonized pathogens, or antibody
dependent cellular cytotoxicity (ADCC) (1, 2). Apart from host defense, IgG autoantibodies
play a major role in tissue destruction and inflammation during autoimmune diseases including
the primary Sjögren’s syndrome, Systemic Lupus Erythematosus or Rheumatoid Arthritis
(3). Moreover, pooled IgG preparations from thousands of donors, called IVIg (intravenous
immunoglobulin G), are used as an anti-inflammatory treatment in the therapy of several
autoimmune diseases, and during chronic inflammation (4).
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The sugar moiety attached to each of two conserved
asparagine 297 residues in the constant domain 2 (CH2) of
the IgG fragment crystallizable (Fc) is essential for both, the
pro- and anti-inflammatory activities of IgG (5) and keeps the
IgG molecule in its typical horseshoe shape critical for FcγR
binding (6–8). Apart from IgG Fc-glycosylation, about 10–15%
of serum IgG contains an N-linked sugar moiety in the IgG
fragment antigen binding (Fab) domain, which is generated de
novo during the process of IgG hypermutation (9, 10). More
recent evidence suggests that IgG Fab glycosylation helps to
regulate IgG specificity (11). With respect to IVIg, especially
terminal sialic acid residues were shown to be responsible for its
anti-inflammatory activity. Thus, while desialylated IVIg lost its
capacity to suppress a wide variety of autoimmune diseases in
mice (12, 13), IVIg preparations enriched for terminal sialic acid
residues showed an enhanced anti-inflammatory activity (5, 14).
Of note, enriching cytotoxic antibodies for terminal sialic acid
residues decreased their activity in vivo and in vitro in some
but not all studies (15). Consistent with this reduced activity a
reduction in affinity of highly sialylated IgGs for select activating
FcγRs was noted (5). Due to the potent immune modulating
functions of select IgG glycoforms, new therapeutic approaches
try to alter IgG activity by modulating its glycosylation ex vivo
(5, 16), or by changing the glycosylation status in the patient by
enzymatic approaches (17–19).
Due to the potent immunomodulatory activity of the
IgG sugar moiety, a precise monitoring of therapeutic
IgG glycosylation has become standard before using new
recombinant antibody preparations or consecutive batches
of already approved antibodies in patients. This in-depth
characterization relies on the fact that once an IgG antibody is
injected into the patient, the sugar structures remain stable and
are not subject to in vivo processing. However, recent studies
suggest that terminal α2,6-linked sialic acids may be attached
independently of the B cell secretory pathway (20, 21). According
to these results, B cell independent IgG sialylation is achieved in
the liver by secreted ST6Gal1 produced by cells lining the liver
central veins. As a sugar donor, CMP-sialic acid at least partially
derived from degranulating platelets may be used. More recently,
it was suggested that in addition to antibodies the surface of
cells may also become sialylated through this process (22). With
respect to therapeutic antibody preparations, these findings raise
the severe concern, that this process may alter the activity of
therapeutic antibodies in the patient. Thus, cytotoxic antibodies
may become less active due to decreased binding to activating
FcγRs, while intravenous IgG preparation may become more
active and may in the worst-case lead to an unwanted strong
immune suppression. Moreover, the genetic heterogeneity
of the human population and age dependent alterations of
immune responses may further complicate to predict how stable
therapeutic antibodies are in individual patients and with respect
to glycosylation.
To address this issue and identify to what extent therapeutic
IgG preparations are subject to B cell independent sialylation, we
made use of two mouse strains lacking either B cells or ST6Gal1,
which is the responsible enzyme for adding terminal sialic acid
residues to the IgG sugar moiety (23–25). Both mouse strains
were injected with human IVIg preparations having either a
normal or strongly reduced level of sialylated IgG glycoforms.
IgG N-glycan analysis by HILIC-UPLC-FLR (plus MS-detection)
and xCGE-LIF of mouse serum for several consecutive days after
IVIg administration revealed that IVIg glycosylation is very stable
upon injection in vivo. Only a very small fraction, predominantly
of disialylated IgG N-glycans attached to the Fab- rather than
the IgG Fc-portion appeared to increase over time. In summary,
our results suggest that B cell extrinsic IgG sialylation may not
modulate therapeutic IgG activity post injection in vivo.
MATERIALS AND METHODS
Mice
C57BL/6 mice were bought from Janvier, µMT−/− mice
were obtained from The Jackson Laboratory. Rag2/γc/
FcεRγ/FcγR2b−/− were generated by breeding Rag2/γc/FcεRγ/
FcγR2b−/− mice (26) with FcγR2b−/− mice. ST6Gal1−/− mice
were kindly provided by Prof. Dr. rer. nat. Lars Nitschke (FAU
Erlangen, Germany). Rag2/γc/FcεRγ/FcγR2b−/−, µMT−/−,
and ST6Gal1−/− mice were kept in the animal facilities of
Friedrich-Alexander-University Erlangen-Nuremberg under
specific pathogen-free conditions in individually ventilated
cages, in accordance with the guidelines of the NIH and the legal
requirements of Germany and the USA. All animal experiments
conducted in the animal facility of the FAU were approved by
government of Lower Franconia.
Reagents
Human IVIg was purchased from Biotest AG (Intratect, 100
mg/ml). α2-3,6,8 neuraminidase was purchased from New
England BioLabs (P0720L, 50,000 U/ml) and used at a
concentration of 0,04 U/µg IVIg. Rituximab (MabThera R©,
Roche) was kindly provided by Prof. Dr. rer. nat Matthias Peipp
(Christian-Albrechts-University Kiel, Germany). TA99-mIgG2c
was purchased from BioXcell (USA),
Fluorescence-Activated Cell Sorting
Analysis
Murine blood was obtained from the retroorbital plexus and
erythrocytes were lysed. To reduce unspecific binding to Fc
receptors, cells were incubated on ice for at least 10min
with Fc-block (clone 2.4G2, 10µg/ml). Cells were washed and
incubated on ice for at least 15min with combinations of
the following antibodies: APC-Fire750-conjugated CD45 (clone
30-F11), BV510-conjugated CD11b (clone M1/70), and PE-
conjugated NKp46 (clone 29A1.4), PE-conjugated Ly6G (clone
1A8), PE-conjugated TCRβ (clone H57-597), and PE-Cy7-
conjugated CD19 (clone 6D5) (all purchased from Biolegend).
FITC-conjugated SNA was purchased from Vector Laboratories.
Analysis was restricted to viable cells, which were identified
by exclusion of cells positive for the nucleic acid binding dye
4’6-diamino-2-phenylindol (DAPI). Experiments were acquired
on a FACS Canto II (BD) and analyzed using FACS Diva
software (BD).
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ELISA
Sera of 8–9 week old C57BL/6, µMT and ST6Gal1−/− mice were
collected and stored at−20◦C until further use. For quantification
of total serum IgM and IgG theMouse IgM ELISAQuantification
Kit and the Mouse IgG ELISA Quantification Kit (Bethyl) were
used according to the manufacturer’s instructions: ELISA plates
were coated with 100 ng/well goat anti-mouse IgM or IgG
in Carbonate/Bicarbonate for 1 h at room temperature. After
washing unspecific binding was blocked with PBS/1% BSA for 1 h
at room temperature. Sera were diluted 1:2,500 (IgM) or 1:10,000
(IgG) in PBS/1% BSA and incubated for 1 h at room temperature
and, after adequate washing, bound IgM and IgG antibodies were
detected by 1:20,000 diluted (in PBS/1% BSA) anti-IgM-HRP or
anti-IgG-HRP antibody in PBS/1% BSA (incubated for 1 h at
room temperature). For detection, TMB Solution was added and
the reaction was stopped with 6% orthophosphoric acid. OD was
measured with VersaMax tunable microplate reader (Molecular
Devices) at 450 and 650 nm. For detection of remaining human
IVIg or neuraminidase treated IVIg in the sera of ST6Gal1−/−
mice the Human IgG ELISA Quantification Kit (Bethyl) was
used according to the above-described protocol. ELISA plates
were coated with 100 ng/well goat anti-human IgG. Sera were
diluted 1:50,000.
In vivo Experiments
10mg IVIg (Intratect, Biotest, Germany), 10mg neuraminidase
treated IVIg (NeuIVIg) or 1mg of the murine antibody
TA99-mIgG2c (BioXcell, USA), which is directed against the
glycoprotein 75 (gp75), was injected into eight- to nine-
week old µMT or ST6Gal1−/− mice. Two, four and six days
after injection sera were collected and analyzed by HILIC-
UPLC-FLR (hydrophilic interaction ultra performance liquid
chromatography with fluorescence detection; IVIg and NeuIVIg
treated serum samples) or xCGE-LIF (multiplexed capillary gel
electrophoresis with laser-induced fluorescence detection; IVIg,
NeuIVIg and TA99 treated serum samples) to analyze IgG
specific glycan structures.
Rituximab-IgG-Induced B Cell Depletion in
PBMC Humanized
Rag2/γc/FcεRγ/FcγR2b−/−
PBMCs were isolated by density centrifugation from individual
buffy coats. Isolated PBMCs were frozen and stored in liquid
nitrogen until further use. Adult Rag2/γc/FcεRγ/FcγR2b−/−
mice were irradiated with 6Gy and injected intraperitoneally
with 1 × 107 human peripheral blood mononuclear cells
(PBMCs) 6 h after irradiation as described previously (27).
Eighteen hours after PBMC transfer, an equal amount of 0.5
µg anti-CD20 rituximab IgG1 (MabThera
R©
) in the serum of
rituximab injectedmice was given intraperitoneally and 24 h later
B cell counts in the peritoneum were analyzed by flow cytometry.
Glycan Analysis
IgG Isolation
The IgG was isolated using protein G monolithic plates (BIA
Separations, Ajdovšcˇina, Slovenia) as described previously (28).
Briefly, 100–400 µl of serum was diluted in ratio 1:7 with 1
× PBS, pH 7.4 and filtered through 0.45µm GHP filter plate
(Pall Corporation, Ann Arbor, MI, USA). After filtration, serum
samples were applied to the protein G plate and instantly washed
with 1 × PBS, pH 7.4, to remove unbound proteins. IgGs
were eluted with 1ml of 0.1M formic acid (Merck, Darmstadt,
Germany) and neutralized with 1M ammonium bicarbonate
(Merck, Darmstadt, Germany).
Sample Preparation for HILIC-UPLC-FLR
Analysis of Glycans
Methanol Desalting
Volumes of eluates corresponding to 100 µg of IgG were dried in
a vacuum concentrator. Samples were then desalted by methanol
precipitation. For methanol desalting 1mL of cold (−20◦C)
methanol (MeOH) was added to each sample and resuspended.
The plate containing samples was then closed with adhesive
seal and centrifuged at 2,200 g for 15min. After centrifugation,
970 µL of MeOH was discarded and 1ml of cold MeOH was
added again to each sample and resuspended. After that, the
plate was again centrifuged at 2,200 g for 15min. After a second
centrifugation, the 970 µL of MeOH again was discarded and the
remaining sample was then dried by vacuum centrifugation.
Glycan Release
The dried, desalted samples were dissolved in 30 µL 1.33%
SDS (w/v) (Invitrogen, Carlsbad, CA, USA) and denatured by
incubation at 65◦C for 10min. After incubation, samples were
left to cool down to room temperature for 30min. Subsequently,
10 µL of 4% Igepal-CA630 (Sigma-Aldrich, St. Louis, MO, USA)
was added to the samples and incubated on a shaker for 15min.
After shaking, 1.2U of PNGase F (Promega, Madison, WI, USA)
in 10 µL 5 × PBS were added and incubated overnight at 37◦C
for N-glycan release.
Glycan Labeling
The released N-glycans were labeled with 2-aminobenzamide (2-
AB). The labeling mixture was freshly prepared by dissolving
2-AB (Sigma-Aldrich, St. Louis, MO, USA) in DMSO (Sigma-
Aldrich, St. Louis, MO, USA) and glacial acetic acid (Merck,
Darmstadt, Germany) mixture (70:30, v/v) and by adding 2-
picoline borane (Sigma-Aldrich, St. Louis, MO, USA) to a final
concentration of 19.2 mg/mL for 2-AB and 44.8 mg/ml for 2-
picoline borane. A volume of 25 µL of labeling mixture was
added to each N-glycan sample in the 96-well plate and the
plate was sealed using adhesive tape. Samples were mixed by a
10min shaking step, followed by 2 h incubation at 65◦C. After
incubation, samples were left to cool down to room temperature
for 30 min.
HILIC-SPE
The samples (in a volume of 75 µL) were mixed with 700 µL of
cold 100% ACN (Sigma-Aldrich, St. Louis, MO, USA). Free label
and reducing agent were removed from the samples usingHILIC-
SPE on a 0.2µm GHP filter plate (Pall Corporation, Ann Arbor,
MI, USA). Solvent was removed by application of vacuum using
a vacuummanifold (Millipore Corporation, Billerica, MA, USA).
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All wells were prewashed using 200 µL of 70% ethanol (Carlo
Erba Reagents, Val de Reuil, France), followed by 200 µL water
and equilibrated with 200 µL of cold 96% ACN. The samples
were loaded onto GHP filter plate and incubated for 2min before
the vacuum application. The wells were subsequently washed 5
× using 200 µL of cold 96% ACN. The last washing step was
followed by centrifugation at 165 × g for 5min. Glycans were
eluted two times with 90 µL of ultrapure water after 15min
of shaking at room temperature followed by centrifugation at
165 × g for 5min. The combined eluates were stored at −20◦C
until usage.
HILIC-UPLC-FLR Analysis of IgG Glycans
Fluorescently labeled N-glycans were separated by HILIC on
a Waters Acquity UPLC instrument (Milford, MA, USA)
consisting of a quaternary solvent manager, sample manager and
a fluorescence (FLR) detector set with excitation and emission
wavelengths of 250 and 428 nm, respectively. The instrument was
under the control of Empower 3 software, build 3471 (Waters,
Milford, MA, USA). The UPLC-FLR system was equipped
with a hydrophilic interaction liquid chromatography (HILIC)
column, a Waters BEH Glycan chromatography column (100
× 2.1mm i.d., 1.7µm BEH particles). The separation used a
gradient of 75% solvent B (100% ACN; solvent A: 100mM
ammonium formate pH 4.4) to 62% solvent B over 27min, with
a flow of 0.4 ml/min. Solvent B was maintained at 62% for
an additional 5min. The column was then washed for 2min
with 100% of solvent A. Initial conditions were restored in
1min and held for an additional 5min to ensure column re-
equilibration. Samples were maintained at 10◦C before injection,
and the separation temperature was 60◦C. The system was
calibrated using an external standard of hydrolyzed and 2-AB
labeled glucose oligomers from which the retention times for the
individual glycans were converted to glucose units (GU). The
chromatographic glycan peaks resulting from the HILIC-UPLC-
FLR analysis were integrated using an automatic processing
method with a traditional integration algorithm after which each
chromatogram was manually corrected to maintain the same
intervals of integration for all samples. The amount of glycans
in each peak was expressed as % of total integrated area. Peak
annotation of human and murine IgG was performed according
to Pucˇic´ et al. (28) and Kristic et al. (29).
HILIC-UPLC-FLR-MS/MS
2AB labeled N-glycans were separated and measured on an
Acquity UPLC H-class instrument coupled to Compact Q-
TOF mass spectrometer via Ion Booster ion source. Both
instruments were operated under HyStar software version 3.2
(Bruker Daltonics). N-glycans were separated on a Waters BEH
Glycan chromatography column, 100 × 2.1mm, 1.7µm BEH
particles, using 100mM ammonium formate, pH 4.4., as solvent
A and acetonitrile as solvent B. Solvent A was prepared by
diluting 2M stock solution of ammonium formate, pH 4.4 with
ultrapure water. For separation linear gradient of 25–38% of
solvent A at the flow rate of 0.4 mL/min in a 32min analytical run
was used. Sample was maintained at 10◦C before injection, while
the separation temperature was 60◦C. Fluorescent detector was
set with excitation and emission wavelengths of 250 and 428 nm,
respectively. Data processing was performed using an automatic
processing method with a traditional integration algorithm after
which each chromatogram was manually corrected to maintain
the same intervals of integration for all the samples. Relative
abundance of each obtained peak was expressed as percentage
of total integrated area. Mass spectrometer was operated in a
positive ion mode with capillary voltage set to 2,250V and
nebulizing gas at pressure of 5.5 Bar. Drying gas (nitrogen) was
applied to source at a flow rate of 4 L/min and temperature of
300◦C, while vaporizer temperature was set to 300◦C and flow
rate of 5 L/min. Nitrogen was used as a source gas, while argon
was used as collision gas. Ion energy was set to 4 eV, transfer
time was 100 µs. Spectra were recorded in m/z range of 50–
3,000 at a 0.5Hz frequency. N-glycan structures were assigned
based on retention time, measured mass and fragmentation
spectra using GlycoMod (30) (http://web.expasy.org/glycomod/)
and GlycoWorkbench (31).
Sample Preparation for xCGE-LIF Analysis
of Glycans
Preparation of Fc and Fab Fractions of Antibodies
IgG-Fc beads (6 µL; CaptureSelectTM IgG-Fc (ms) Affinity
Matrix, Thermo Scientific, USA) were dispensed into each well
of Orochem filter plate (Orochem Technologies Inc., USA) in
order to capture antibodies through their Fc region and washed
three times with 200 µl 1× PBS (pH 7.4) on a vacuum manifold.
Eluates obtained after isolation on Protein G plate were added
to each well of the Orochem filter plate in a volume ranging
from 200 to 400 µL (∼90 µg of antibody) and incubated for
1 h at room temperature. Samples were washed four times with
200 µL 1 × PBS (pH 7.4) to remove unbound antibodies.
The recombinant streptococcal IdeS enzyme (FabRICATOR,
Genovis, Lund, Sweden; 1U per 1 µg of protein) was combined
with 35 µL 1 × PBS (pH 6.6) and added to each sample.
Samples were incubated in a humid chamber at 37◦C for 18 h.
Fab fractions were collected by centrifugation for 2min at 50× g
in a PCR plate (Thermo Fischer Scientific, MA, USA). Remaining
Fc fractions were washed three times with 200 µl 1 × PBS (pH
7.4) and additional three times with 200 µl ultrapure water. For
elution of Fc fragments, 100 µL od 0.1M formic acid (pH 2.5)
was added to each well of Orochem filter plate and neutralized
with 17 µL 1M ammonium bicarbonate. Fc fragments were
collected in a clean PCR plate and neutralized with 17 µL 1M
ammonium bicarbonate.
Methanol Desalting
Volumes of IgG eluates corresponding from 3 to 10 µg of IgG
were dried in a vacuum concentrator and desalted following
previously described protocol for methanol precipitation.
N-Glycan Release
The dried, desalted samples were dissolved in 3 µL of 1.66
× PBS with 4 µL 0.5% SDS (w/v) (Invitrogen, Carlsbad, CA,
USA) and denatured by incubation at 65◦C for 10min. After
incubation, 2 µL of 4% Igepal-CA630 (Sigma-Aldrich, St. Louis,
MO, USA) was added to the samples and incubated on a shaker
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for 15min. After shaking, 1.2U of PNGase F (Promega, Madison,
WI, USA) in 1 µL 5 × PBS was added and incubated for 3 h
at 37◦C for N-glycan release. Samples were dried in a vacuum
concentrator afterward.
Glycan Labeling and HILIC-SPE
Dried samples were labeled with 8-aminopyrene-1,3,6-trisulfonic
acid (APTS, Sigma-Aldrich, St. Louis, MO, USA) and cleaned
by HILIC-SPE on BioGel P10 (Bio-Rad, Hercules, CA, USA) in
96-well format as described previously (32).
Multiplexed Capillary Gel Electrophoresis With
Laser-Induced Fluorescence (xCGE-LIF)
First xCGE-LIF measurement was carried out without internal
normalization standard to visually assess signal intensities in
the samples. Reaction mixture consisted of 3 µl of N-glycan
post-cleanup eluate, 1 µl GeneScan 500 LIZ Size Standard
(Applied Biosystems, Foster City, CA, USA; 1:50 dilution in Hi-
Di Formamide) and 6µl Hi-Di Formamide (Applied Biosystems,
Foster City, CA, USA) pipetted into MicroAmp Optical 96-
well Reaction Plate (Applied Biosystems, Foster City, CA,
USA), sealed with a 96-well plate septa (Applied Biosystems,
Foster City, CA, USA) and briefly centrifuged to avoid air
bubbles at the bottom of the wells. Second measurement was
also carried out in total volume of 10 µl and contained 3
µl of N-glycan post-cleanup eluate (depending on the signal
intensity in the first xCGE-LIF run), 1 µl GeneScan 500 LIZ
Size Standard (1:50 dilution in Hi-Di Formamide), 1 µl of
NormMix (glyXera, Magdeburg, Germany) in Hi-Di Formamide.
The xCGE-LIF measurement was performed in a 3130 Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA), equipped
with a 50 cm 4-capillary array filled with POP-7 polymer (Applied
Biosystems, Foster City, CA, USA). Electrokinetic sample
injection was performed at 7.5–15 kV for 5 or 10 s depending on
the signal intensity; samples were analyzed with a running voltage
of 15 kV and run time of 3,400 s. Raw data files were converted
to.xml file format using DataFileConverter (Applied Biosystems,
Foster City, CA, USA) and analyzed using the glycan analysis
tool glyXtool
TM
(glyXera, Magdeburg, Germany). GlyXtool
TM
software was used for structural identification by patented
migration time normalization to an internal standard and N-
glycan database driven peak annotation, for data comparison and
for integration of normalized peak heights (33, 34).
Statistical Analysis
The statistical significance of the data was determined as
indicated in the figure legends. In brief, the Kruskal-Wallis
test, followed by Dunn‘s multiple comparison test, or repeated
measures two-way ANOVA with Bonferroni post-test were used
to determine statistical differences between more than two
groups. To indicate different levels of significance, a p 0.05 was
assigned one asterisk, a value smaller than 0.05 but larger than
0.001 was assigned two asterisks and a value smaller than 0.001
was assigned three asterisks.
RESULTS
Model System to Study B Cell Independent
Sialylation of Therapeutic IgG
To determine to what extent therapeutic IgG preparations are
subject to B cell independent sialylation, we made use of two
mouse strains, namely ST6Gal1 deficient (ST6Gal1−/−) and
µMT mice. While ST6Gal1−/− mice lack the sialyltransferase 1,
catalyzing the addition of α2,6 linked sialic acid residues (23, 35),
µMT mice have a disruption of the gene encoding the µ-chain
constant region resulting in an arrest of B cell development at
the pre-B-cell stage (36). As shown in Figure 1, we started with
a characterization of the two in vivo model systems with respect
to B cell development and the presence of a2,6-linked sialic acid
residues. As expected, µMT mice had no B cells in the blood,
while the amount of B cells of ST6Gal1−/− mice was comparable
to C57BL/6 mice (Figure 1A). Consistent with the absence of B
cells in µMT mice, no IgM and IgG antibodies were detectable
in the serum (Figure 1B). In contrast, ST6Gal1−/− mice showed
normal levels of B cells, strongly reduced levels of serum IgM
and a trend toward higher levels of serum IgG as described
before (Figure 1B) (35, 37). Staining with SNA (sambucus nigra
agglutinin)—a plant lectin specifically detecting α2,6 linked sialic
acids—demonstrated that ST6Gal1−/− mice were negative for
SNA on B and T cells, whereas µMT mice showed a T cell
SNA staining pattern comparable to C57BL/6 mice (Figure 1C).
Finally, the serum IgG glycosylation pattern of C57BL/6, µMT
and ST6Gal1−/− mice was analyzed by HILIC-UPLC-FLR
confirming the absence of a2,6 linked sialic acid species on
serum IgG of ST6Gal1−/− mice (Figure 1D). In addition, we
analyzed the sugar structures present in IVIg and neuraminidase
digested IVIg preparations (NeuIVIg), which were used for
studying B cell independent sialylation in vivo (Figure 1D). As
expected, no sialic acid containing sugar moieties were detectable
in neuraminidase digested IVIg, allowing a detection of extrinsic
de novo sialylation in vivo with the greatest possible sensitivity.
Analysis of B Cell Extrinsic IVIg Sialylation
in vivo
To address if therapeutic IgG preparations are subject to B
cell extrinsic de novo sialylation in vivo, we injected 10mg
IVIg in B cell deficient µMT mice and analyzed alterations in
IVIg glycosylation in the serum of these animals by hydrophilic
interaction ultra-performance liquid chromatography with
fluorescence detection (HILIC-UPLC-FLR). In addition, the
identity of each peak, were sialylation was expected (GP15–
26), was confirmed by mass spectrometry (fragmentation spectra
see Figure S1). As mouse IgG glycans terminate with N-
glycolylneuraminic acid (Neu5Gc), while human IgGs carry
terminal N-acetylneuraminic acids (Neu5Ac), the injection of
human IgG into mice allows an unequivocal detection of B
cell independent sialylation (29, 38–40). An overview of all
detected murine and human glycan structures is shown in
Figure S2. When we compared the HILIC-UPLC-FLR profiles
of IVIg before and 6 days after injection in µMT mice we
found that the IVIg glycosylation profiles overlapped almost
completely (Figure 2A). However, some small additional glycan
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FIGURE 1 | Characterization of the experimental system to study extrinsic IgG sialylation. (A–C) C57BL/6, µMT, and ST6Gal1−/− mice were analyzed for the
presence of B cells in the blood by FACS analysis (A), serum IgM and IgG by ELISA (B) as well as for the presence of a2,6-linked sialic acid residues on the surface of
B and T cells by staining with sambucus nigra agglutinin (SNA). (D) Shown are representative glycoanalysis of serum IgG from the indicated mouse strains and of IVIg
or neuraminidase treated IVIg (NeuIVIg) by HILIC-UPLC-FLR. Statistical significance was evaluated with a one-way ANOVA test and a Bonferroni correction.
**p = 0.01, ****p = 0.0001. Horizontal lines in (B) represent mean values (n = 10–20). SSC, side scatter; EU, emission units.
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FIGURE 2 | Detection of de novo sialylated IgG glycoforms in vivo. (A) Shown is an overlay of a representative HILIC-UPLC-FLR analysis of IVIg before and 6 days
after injection into µMT mice (µMT IVIg d6). (B) Depicted is an overlay of a HILIC-UPLC-FLR analysis of mouse serum IgG and IVIg 6 days post injection into µMT
mice. Enlarged insets highlight additional glycan peaks (GP) that were not present in the original IVIg preparation. Schematic drawings of the most prominent sugar
structures (mouse structures on top, human structures on the bottom) are assigned to the respective peaks. Legend at the bottom of the figure explains the symbols
used for individual sugar structures. See also Figure S2 for additional peak information.
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peaks (GP20, GP25, GP26) were detected that were not present
in the original IVIg preparation (enlarged inset in Figure 2A).
Interestingly all of those novel glycan peaks overlapped with sialic
acid containing sugar structures (GP20 containing one sialic acid
residue, GP25 and GP26 containing two sialic acid residues with
(GP26) or without (GP25) fucose) selectively present in serum
IgG from C57BL/6 mice (Figure 2B), suggesting that a very small
level of extrinsic sialylation of IVIg can occur in mice.
We next analyzed the kinetics of B cell independent IgG
sialylation by studying changes in IVIg sialylation 2, 4, and 6
days after injection into µMT mice (Figure 3 and Figure S3).
As some studies suggest, that the level of IgG sialylation may
affect antibody half-life and FcRn binding (41, 42), we first
assessed if both, sialylated and non-sialylated IVIg preparations
had a comparable half-life. As shown in Figure S3A, however,
we noted no effect in the half-life of sialylated and asialylated
IVIg (5), ensuring that both IVIg preparations had a comparable
chance to become resialylated in vivo. Indeed, the presence
of both disialylated sugar structures (GP25 and 26) slowly
increased over time (Figure 3A). To increase the amount of
acceptor sites for extrinsic IgG sialylation we also injected
IVIg pretreated with neuraminidase (NeuIVIg). As shown in
Figure 3B, however, this only mildly increased the level of
extrinsic IgG sialylation on afucosylated sugar moieties, despite
the availability of large amounts of IgG-G2 glycosylation variants.
In total, only 1% of IgG glycovariants present in NeuIVIg
acquired a disialylated sugar moiety 6 days after injection into
µMT mice. To further validate these results, we repeated this
experiment in ST6Gal1−/− mice, which are not able to add α2,6-
linked sialic acid residues and therefore served as a negative
control. As shown in Figures 3C,D and Figure S3, the sialylation
of IVIg or neuraminidase digested IVIg did not change over
time in these animals, suggesting that the increase in GP25 and
GP26 were indeed due to de novo IgG sialylation by ST6Gal1.
In contrast, the small increase in monosialylated fucosylated IgG
glycostructures (GP20) was also evident in ST6Gal1 deficient
mice (Figures S3B,C). Moreover, afucosylated monosialylated
glycan forms (GP18, A2G2Z1) of IVIg or NeuIVIg (Figure 4B)
did not increase over time (Figure S3). Importantly however, the
monosialylated glycoforms in GP18 comprise almost completely
of human FA2G2S1 and it is therefore difficult to quantify
murine monosialylated glycostructure by HILIC-UPLC-FLR.
This prompted us to perform further studies.
Detection of B Cell Extrinsic IgG Sialylation
by xCGE-LIF
To ensure that the inability to detect changes in de novo generated
monosialylated IgG glycoforms was not due to technical reasons,
we decided to use multiplexed capillary gel electrophoresis with
laser-induced fluorescence detection (xCGE-LIF) to confirm our
results. The advantage of xCGE-LIF is that very small amounts of
IgG preparations can be analyzed with high sensitivity allowing
better resolution for sialylated species. The characteristic glycan
profiles of murine and human IgG preparations by xCGE-
LIF as well as the structure and peak assignment are depicted
in Figure S4. Based on the fact that neuraminidase digested
IVIg allowed the most clear-cut identification of de novo IgG
sialylation in vivo, we focused on NeuIVIg-injected µMT and
ST6Gal1−/− mice (Figures 4, 5). As shown for HILIC-UPLC-
FLR analysis, additional glycan peaks became detectable on
NeuIVIg 6 days after injection in B cell deficient µMT mice,
which overlapped with IgG sugar structures selectively present
on mouse but not human IgG (Figure 4B). Fully consistent
with HILIC-UPLC-FLR, the glycan peaks that appeared de novo
and were increasing over time were mono- (P11 and P13)
and disialylated sugar structures (P2 and P4) with (P4 and
P13) or without (P2 and P11) core-fucose (Figures 4, 5).
Injection of NeuIVIg into ST6Gal1−/− mice did not lead to any
detectable changes in IVIg sialylation in vivo (Figures 5B,C).
Moreover, agalactosylated (G0), mono-galactosylated (G1), and
digalactosylated (G2) IgG glycoforms were not changed over time
(Figure S5). Thus, xCGE-LIF analysis allowed a better detection
of mono- and disialylated IgG sugar structures.
To exclude that the observed minimal level of extrinsic IgG
sialylation is due to the use of human IgG in mice, we performed
a similar experiment where we injected 1mg of the murine
TA99-IgG2c antibody—directed against the glycoprotein 75—
into B cell deficient µMT mice and analyzed alterations in IgG
glycosylation in the serum of these animals 10min as well as 2, 4,
and 6 days after injection by xCGE-LIF. As shown in Figure S6
murine IgG acquired sialic acid residues to a similar extend as
human IgG. Again, especially disialylated sugar structures (P2
and P4) were increasing over time. The sugar structure FA2G2Z1
(P13) might co-migrate with the large peak present in initial
TA99-mIgG2c antibody (around 250MTU”) and therefore could
not be clearly distinguished. In summary, the data obtained with
HILIC-UPLC-FLR and xCGE-LIF analysis suggest that a very
small amount of IgG molecules—both human and murine—
containing two galactose residues can become modified with one
or two sialic acid residues in vivo in the absence of B cells.
To further characterize extrinsic IgG sialylation, we also
discriminated de novo generated IgG glycoforms between Fab
and Fc. For this purpose, the isolated serum IgG preparations
from NeuIVIg injected µMT mice (4 days after NeuIVIg
injection) were separated into Fab and Fc portions before
glycoanalysis by xCGE-LIF. Individual analysis of the separated
IgG fragments revealed that extrinsic IgG sialylation occurred
almost exclusively onN-glycosylation sites of the Fab (Figure 6A)
but not of the Fc (Figure 6B) fragment. Again, minimal amounts
of especially disialylated IgG sugar structures were appearing.
In the two mouse serum samples 1.57 ± 0.3% of all IgG
glycoforms on the Fab fragment corresponded to disialylated
sugar structures, while only 0.89 ± 0.15% were monosialylated.
In contrast, no additional murine sialic acids could be detected
on the Fc fragment (Figure 6B). Therefore, predominantly the N-
linked sugar moieties of the easily accessible Fab fragment in the
IVIg preparations seems to be the target for de novo sialylation.
Impact of Extrinsic Sialylation on IgG
Effector Function
To evaluate the impact of extrinsic sialylation on cytotoxic
IgG effector functions, we injected µMT and ST6Gal1−/− mice
with the CD20 specific antibody rituximab, which is broadly
used in patients with autoimmune diseases and cancer. As
rituximab selectively recognizes human but not mouse CD20,
the injection into ST6Gal1 deficient mice with Rituximab does
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FIGURE 3 | Kinetics of extrinsic IgG sialylation in µMT and ST6Gal1 deficient mice. Shown are the relative changes (% of total IgG glycoforms in the preparation) in
glycopeaks (GP) 25 and 26 in IVIg (A,C) or neuraminidase treated IVIg (B,D) before (IVIg or NeuIVIg) and 2, 4, and 6 days after injection into µMT (A,B) or ST6Gal1
deficient mice (C,D) by HILIC-UPLC-FLR analysis. Changes in the respective glycopeak in individual mice are shown at the top of each figure (n = 4–5). The bottom of
each Figure shows a representative HILIC-UPLC-FLR trace of GP25 and 26. In each subfigure a schematic drawing of the sugar structure for GP25 and 26 is
depicted. The Figure legend at the bottom explains the symbols used for the schematic representation of the sugar moieties.
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FIGURE 4 | Detection of de novo sialylation of human IgG in vivo by xCGE-LIF. (A) Depicted are representative overlays of xCGE-LIF IgG glycoanalysis of
neuraminidase treated IVIg (NeuIVIg) before and 6 days after injection into µMT mice (µMT NeuIVIg d6). (B) Shown are representative overlays of xCGE-LIF
glycoanalysis of serum IgG from C57BL/6 mice or from µMT mice 6 days post injection with neuraminidase treated IVIg. Schematic drawings of the sugar moieties are
depicted for the major peaks. Enlarged insets emphasize peaks detected selectively on NeuIVIg 6 days post injection into µMT mice. The Figure legend at the bottom
of the Figure depicts the symbols used for individual sugar residues. See also Figure S2 for additional peak information. MTU”, normalized migration time units.
not affect B cell numbers. Four days after injection, serum
from µMT and ST6Gal1 knockout mice was collected, the
level of human IgG determined and extrinsic IgG sialylation
assessed by xCGE-LIF. As shown in Figure 7A, very low
amounts of exclusively disialylated IgG structures were found
in rituximab injected µMT mice. To assess the functional
activity of human CD20 antibodies present in the serum
of µMT and ST6Gal1 deficient mice, a serum equivalent
containing 0.5 µg rituximab was injected into immunodeficient
Rag2/γc/FcεRγ/FcγR2b−/− mice, which were irradiated and
reconstituted with human peripheral blood mononuclear cells
18 h before (Figure 7B). As shown in Figures 7C,D, rituximab
treatment via serum transfer of rituximab-injected µMT and
ST6Gal1−/− mice led to a significant depletion of B cells in
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FIGURE 5 | Kinetics of appearance of de novo sialylated IgG glycoforms as detected with xCGE-LIF. (A,B) Shown are the relative changes (% of total IgG glycoforms
in the preparation) in glycopeaks (P) 2 and 4 in neuraminidase treated IVIg (NeuIVIg) before and 2, 4, and 6 days after injection into µMT (A) or ST6Gal1 deficient mice
(B) by xCGE-LIF analysis for individual mice. In the bottom of each Figure a representative xCGE-LIF trace of glycopeaks P2 and 4 is depicted. (C) Quantification of all
sialylated glycan peaks P2, P4, P11, and P13 2, 4, and 6 days after injection of NeuIVIg into µMT or ST6Gal1−/− mice, respectively. Bars represent mean ± SD. *p =
0.05, **p = 0.01, ***p = 0.001 by repeated measures two-way ANOVA. n = 4–5. In each Figure, a schematic drawing of the sugar structure for the respective
glycopeak is depicted. MTU”, normalized migration time units; n.d., not detectable.
the peritoneal cavity, while B cell counts in PBS-serum treated
mice were not affected. In line with the low efficiency of
the extrinsic sialylation pathway, when we compared B cell
depletion between rituximab-containing ST6Gal1−/− and µMT
serum, no significant differences in cytotoxic antibody activity
were detected.
DISCUSSION
An important step in the process of introducing a new
therapeutic IgG antibody or a new batch of an already approved
antibody into the clinic is an in-depth characterization of the
IgG glycovariants present in the antibody preparation. It is
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FIGURE 6 | Discrimination of de novo sialylation of human IgG in vivo between Fab and Fc fragments. (A,B) Serum IgG preparations of µMT mice injected with
neuraminidase treated IVIg (NeuIVIg) were digested to generate Fab and Fc fragments. To identify de novo generated IgG sugar structures on the individual
N-glycosylation sites, individual fractions were analyzed separately by xCGE-LIF. Depicted are representative overlays of IgG Fab- (A) and Fc-portion (B) specific
xCGE-LIF glycoanalysis of C57BL/6 mice, the injected NeuIVIg preparation before injection as well as NeuIVIg 4 days after injection into µMT mice. Schematic
drawings of the sugar moieties are depicted for the major peaks. Enlarged insets emphasize peaks detected selectively on NeuIVIg 4 days post injection into µMT
mice. The Figure legend at the bottom of the Figure depicts the symbols used for individual sugar residues. See also Figure S2 for additional peak information. MTU”,
normalized migration time units.
well-known that many factors, such as the cell line in which
a therapeutic antibody is produced (43) or the specific culture
conditions (44), can alter IgG glycosylation. The importance of
detecting alterations in IgG glycosylation have been emphasized
by the fact that relatively minor changes in the composition of
the biantennary complex sugar structure attached to both of the
IgG Fc-domains can dramatically alter IgG activity. Thus, IgG
antibodies lacking fucose, sialic acid, and galactose have been
described to have an enhanced pro-inflammatory activity, while
antibody glycoforms rich in terminal sialic acid residues have
an active anti-inflammatory and immunomodulatory activity (5,
14, 45, 46). Until recently, it was believed that IgG glycosylation
is established exclusively within the cells in which the antibody
is produced and remains rather stable upon injection in vivo.
However, more recent evidence suggests that IgG glycosylation
may be actively altered in vivo (20, 21, 47). Thus, IgG antibodies
were described to become sialylated post secretion from plasma
cells. As enhanced IgG sialylation was shown to impact IgG
activity, this would represent a major concern for the use of
therapeutic antibodies in patients, prompting us to analyze
to what extent this extrinsic IgG sialylation pathway affects
passively transferred antibodies. Technically this represents a
major challenge as in vivo several factors may lead to an altered
abundance in IgG glycoforms over time. For example, a more
rapid clearance of select IgG isotypes or glycoforms may lead
to an increase in other IgG glycoforms with a longer IgG
half-life (41, 48). In a similar manner, using mouse strains
with a cell subset specific deletion of ST6Gal1, the enzyme
that catalyzes the addition of α2,6-linked terminal sialic acid
residues on IgG antibodies, may overestimate the level of B cell
extrinsic sialylation if the deletion in the target cell population
is incomplete and if B cell subsets that have escaped ST6Gal1
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FIGURE 7 | Impact of IgG de novo sialylation on cytotoxic antibody activity. Shown is a representative overlay of xCGE-LIF IgG glycoanalysis of rituximab (RTX)
treated µMT mice (A), a schematic overview of the experimental setup (B), and its respective results (C,D). (A) µMT mice were injected with 400 µg RTX (µMT RTX)
and 4 days later serum IgG was analyzed by xCGE-LIF to identify de novo generated IgG glycoforms. Schematic drawings of the sugar moieties are depicted for the
major peaks. Enlarged insets emphasize peaks detected selectively on RTX 4 days post injection into µMT mice. (B) Immunodeficient Rag2/γc/FcεRγ/FcγR2b−/−
mice were irradiated (6Gy) and reconstituted with human PBMC in the peritoneal cavity. Eighteen hours later mice (n = 5–6) received equal amounts of rituximab (0.5
µg/20 g mouse) derived from µMT or ST6Gal1−/− mice, which had been injected with rituximab 4 days before. Twenty-four hours after RTX injection, cells of the
peritoneal cavity were analyzed by flow cytometry. Shown are representative FACS plots (C) and the quantification (D) of human B cell counts in the peritoneal cavity 1
day after rituximab or PBS injection. Statistical significance was evaluated with a Kruskal-Wallis test followed by Dunns post-hoc test. **p = 0.01, ***p = 0.001.
Horizontal lines represent median values.
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deletion have a competitive advantage over those with a deletion
of the enzyme.
To study this in a most informative setting we decided to
analyze changes in human IgG sialylation in mice lacking mature
B cells and serum antibodies. To get the most complete picture
we used human intravenous immunoglobin preparations (IVIg),
as IVIg contains all human IgG subclasses present in serum.
In this experimental scenario, human IgG molecules represent
the only antibody isotype in the serum and hence should be
fully accessible for de novo sialylation. Moreover, mouse terminal
sialic acid residues (Neu5Gc) can be distinguished from human
sialic acid residues (Neu5Ac) by analytical techniques allowing
an unequivocal identification of newly added mouse derived
sialic acid residues to the transferred human antibodies in vivo
(38). By using two independent analytical techniques to assess
extrinsic de novo IgG sialylation in vivo, our results suggest
that the addition of sialic acid residues is a very rare, but
nonetheless detectable event. Interestingly the acceptor sugar
moieties accessible for the de novomono- or disialylation seemed
to contain two terminal galactose residues (G2 glycoform), while
in principle also monogalactosylated (G1) glycoforms could
have served as acceptor structures for de novo sialylation and
are normally present in mice in vivo. Moreover, both core
fucosylated G2 and non-fucosylated G2 sugar moieties were able
to acquire terminal Neu5Gc. Of note, increasing the amount of
potential acceptor sugar structures by pre-treating human IgG
with neuraminidase only marginally increased the level of IgG
sialylation, further strengthening the notion, that extrinsic IgG
sialylation is a rather inefficient process. However, it has to be
considered that also the monosialylated structures as potential
acceptor structures were removed. More importantly, when IgG
preparations such as IVIg were used, in which IgG molecules
present additionally containing N-linked sugar moieties in the
Fab portion as potential acceptor sites for extrinsic sialylation,
an almost exclusive sialylation occurred in these more easily
accessible sugar domains (although not at a higher efficacy). As
Fab arm glycosylation may modify antibody specificity, it will
be interesting to study if extrinsic Fab arm glycosylation affects
target antigen binding (49). If no Fab associated sugar moieties
were present, however, minor changes in Fc-linked sugar
moieties could be detected for mouse and human monoclonal
antibodies. As the extent of B cell extrinsic IgG sialylation was
similar for mouse and human IgG, we would exclude that human
IgG molecules become sialylated less efficiently in mice due to
some species barrier effects. Furthermore, as the amount of de
novo sialylated IgG never exceeded two percent of the total IgG
present in vivo, one would not expect functional consequences
for IgG activity. Indeed, the human CD20 specific antibody
Rituximab did not show an altered activity when passaged
through B cell deficient mice.
In summary, our study demonstrates that the process
of B cell extrinsic de novo sialylation of IgG antibodies
in vivo is only affecting a minor subset in the pool of IgG
glycovariants present in IVIg and cytotoxic IgG preparations
and hence may not trigger altered pro- or anti-inflammatory
IgG activities.
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